Market by Type, Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030
Triton’s research report examines that the Asia-Pacific ophthalmic drugs market is estimated to achieve revenue at 7.56% of CAGR during the forecast years 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The countries examined in this region include:
•       Â
China
•       Â
Japan
•       Â
South Korea
•       Â
India
•       Â
ASEAN Countries
•        Australia &
New Zealand
•       Â
Rest of Asia-Pacific
The Asia-Pacific
ophthalmic drugs market is undergoing a massive transformation owing to the
region’s demographic shift, expansion of healthcare infrastructure, innovation,
and technological advancements in the pharmaceutical industry. Additionally, the
introduction of digital health services and telemedicine helps to address the
accessibility issues in remote areas, thereby providing early diagnosis,
delivery, and management of ophthalmic drug products for eye care treatments. Â
China leads the ophthalmic drugs market
with the highest share.
This is due to an increase in the age-old
population, their changing lifestyle patterns, eye disorders, cataracts,
and diabetic retinopathy. A surge in these conditions will further lead to a
wide use of ophthalmic drugs in the coming years. Moreover, innovation in ophthalmic drug development coupled with
investments by pharmaceutical companies to research and develop effective eye
care solutions will further drive the studied market’s growth across the
nation.
Similarly, the ophthalmic drugs market has experienced pivotal
growth in South Korea, primarily driven by growing awareness regarding eye
health. The rising concern for eye-related disorders due to aging and long
exposures to digital screens has increased the demand for these drugs. This
country is also witnessing mergers and collaborations with new entrants and
healthcare providers to offer an accessible variety of eye care treatment
products and expand the ophthalmic drugs market.
The
most commonly used and convenient ophthalmic drug is eye drops. They are a type
of liquid dosage that provides targeted therapy to prevent microbial
contamination and minimize the risk of irritation. In order to treat glaucoma,
dry eye syndrome, allergic conjunctivitis, and bacterial conjunctivitis, eye
drops are formulated and manufactured under strict aseptic conditions to ensure
their sterility. The growth of the ophthalmic drugs market is determined based on type, condition, delivery method,
therapeutic type, and channel. The delivery method
segment is branched into gels, eye solutions and suspensions, capsules and tablets,
eye drops, and ointments.Â
Major market players leading in the ophthalmic
drugs market
include Sun Pharmaceutical Industries Ltd, AbbVie Inc, Bausch Health Companies Inc, Regeneron
Pharmaceuticals Inc, Accutome Inc, Genentech Inc, Pfizer Inc, Thea
Pharma Inc, Novartis AG, and Johnson & Johnson.
Sun
Pharmaceutical Industries Ltd is a pharmaceutical company offering branded
generics and products for treating psychiatric, nephrological,
gastroenterological, heart diseases, orthopedic, neurological, and
ophthalmologic diseases. The drugs are offered in several forms, like
injectables, inhalers, tablets, capsules, creams, ointments, and liquids. It is
headquartered in Mumbai, India and has manufacturing facilities across North
America, Latin America, and Asia-Pacific.
KEY
DELIVERABLES OF THE REPORT:
â—ŹÂ Â Â Â Â
Market CAGR during the forecasting years 2023-2030
â—ŹÂ Â Â Â Â
Detailed data highlighting key insights, industry components, and
market strategies
â—ŹÂ Â Â Â Â
Comprehensive information and estimation of the ophthalmic
drugs
market revenue growth in the Asia-Pacific and its influence on the parent
market
â—ŹÂ Â Â Â Â
In-depth study of forthcoming trends in consumer behavioral
patterns
â—ŹÂ Â Â Â Â
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
â—ŹÂ Â Â Â Â
A wide-ranging study of factors that will challenge the APAC ophthalmic
drugs
market’s growth during the upcoming years
Want to get specific
insights? Our team of analysts can customize this report based on your
preferences. Connect with us here.Â
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TECHNOLOGY
SNAPSHOT
2.2. IMPACT
ANALYSIS ON THE OPHTHALMIC DRUGS MARKET
2.2.1. COVID-19
IMPACT ON THE OPHTHALMIC DRUGS MARKET
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. REGULATORY
FRAMEWORK
2.6. KEY
BUYING IMPACT ANALYSIS
2.7. KEY
MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. MERGERS
& ACQUISITIONS
2.8. MARKET
DRIVERS
2.8.1. AGING
POPULATION VULNERABLE TO EYE DISORDERS
2.8.2. PROGRESS
IN DRUG DELIVERY TECHNOLOGIES
2.8.3. ESCALATING
INCIDENCE OF OCULAR DISEASES
2.8.4. REIMBURSEMENT
POLICIES BY HEALTHCARE SYSTEMS
2.9. MARKET
CHALLENGES
2.9.1. CHALLENGING
TIMELINES FOR PRODUCT APPROVAL
2.9.2. ADVERSE
EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE
2.10. MARKET
OPPORTUNITIES
2.10.1. SURGE
IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGSÂ
2.10.2. INCREASE
IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES
2.11. ANALYST
PERSPECTIVE
3. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET – BY TYPE
3.1. PRESCRIPTION
DRUGS
3.2. OVER-THE-COUNTER
DRUGS
4. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET – BY CONDITION
4.1. DRY
EYE
4.2. GLAUCOMA
4.3. INFECTION/INFLAMMATION/ALLERGIES
4.4. RETINAL
DISORDER
4.4.1. WET-AGE
RELATED MACULAR DEGENERATION
4.4.2. DRY-AGE
RELATED MACULAR DEGENERATION
4.4.3. DIABETIC
RETINOPATHY
4.4.4. OTHER
RETINAL DISORDERS
4.5. OTHER
CONDITIONS
5. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE
5.1. ANTI-GLAUCOMA
5.2. ANTI-INFECTION
5.3. ANTI-INFLAMMATORY
5.4. ANTI-ALLERGY
5.5. OTHER
THERAPEUTIC TYPES
6. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD
6.1. GELS
6.2. EYE
SOLUTIONS & SUSPENSIONS
6.3. CAPSULES
& TABLETS
6.4. EYE DROPS
6.5. OINTMENTS
7. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET – BY CHANNEL
7.1. HOSPITAL
PHARMACIES
7.2. DRUG
STORES
7.3. ONLINE
PHARMACIES
7.4. OTHER
CHANNELS
8. ASIA-PACIFIC
OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK
8.1. CHINA
8.1.1. CHINA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2. JAPAN
8.2.1. JAPAN
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3. INDIA
8.3.1. INDIA
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.4. SOUTH
KOREA
8.4.1. SOUTH
KOREA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5. ASEAN
COUNTRIES
8.5.1. ASEAN
COUNTRIES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.6. AUSTRALIA
& NEW ZEALAND
8.6.1. AUSTRALIA
& NEW ZEALAND OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.7. REST
OF ASIA-PACIFIC
8.7.1. REST
OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
9. COMPETITIVE
LANDSCAPE
9.1. ABBVIE
INC
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.1.3. KEY
STRENGTHS
9.1.4. KEY
CHALLENGES
9.2. BAUSCH
HEALTH COMPANIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. JOHNSON
& JOHNSON
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. NOVARTIS
AG
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. REGENERON
PHARMACEUTICALS INC
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.5.3. KEY
STRENGTHS
9.5.4. KEY
CHALLENGES
9.6. SUN
PHARMACEUTICAL INDUSTRIES LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY
STRENGTHS
9.6.4. KEY
CHALLENGES
9.7. ACCUTOME
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY
STRENGTHS
9.7.4. KEY
CHALLENGES
9.8. GENENTECH
INC
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.8.3. KEY
STRENGTHS
9.8.4. KEY
CHALLENGES
9.9. THEA
PHARMA INC
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.9.3. KEY
STRENGTHS
9.9.4. KEY
CHALLENGES
9.10. PFIZER
INC
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY
STRENGTHS
9.10.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2023-2030 (IN
$ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 8: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030
(IN $ MILLION)
TABLE 9: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2023-2030 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD,
2023-2030 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN
$ MILLION)
FIGURE 1: TECHNOLOGY SNAPSHOT
FIGURE 2: MARKET MATURITY ANALYSIS
FIGURE 3: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030
(IN %)
FIGURE 4: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER
DRUGS, 2023-2030 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 &
2030 (IN %)
FIGURE 7: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN
$ MILLION)
FIGURE 8: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030
(IN $ MILLION)
FIGURE 9: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY
INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2023-2030 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER,
2022 & 2030 (IN %)
FIGURE 12: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED
MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED
MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY,
2023-2030 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL
DISORDERS, 2023-2030 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS,
2023-2030 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE,
2022 & 2030 (IN %)
FIGURE 18: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA,
2023-2030 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION,
2023-2030 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY,
2023-2030 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY,
2023-2030 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC
TYPES, 2023-2030 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022
& 2030 (IN %)
FIGURE 24: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $
MILLION)
FIGURE 25: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS &
SUSPENSIONS, 2023-2030 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CAPSULES &
TABLETS, 2023-2030 (IN $ MILLION)
FIGURE 27: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030
(IN $ MILLION)
FIGURE 28: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030
(IN $ MILLION)
FIGURE 29: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 &
2030 (IN %)
FIGURE 30: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 31: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRUG STORES,
2023-2030 (IN $ MILLION)
FIGURE 32: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 33: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS,
2023-2030 (IN $ MILLION)
FIGURE 34: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2022
& 2030 (IN %)
FIGURE 35: CHINA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 36: JAPAN OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 37: INDIA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 38: SOUTH KOREA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 39: ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)
FIGURE 40: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET, 2023-2030
(IN $ MILLION)
FIGURE 41: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)